All study population | Triple | Dual | Mono | p value | |
---|---|---|---|---|---|
Patients’ characteristics | (n = 1241) | (n = 1073) | (n = 104) | (n = 64) | – |
Male gender, n (%) | 988 (79.6%) | 853 (79.5%) | 86 (82.7%) | 49 (76.6%) | 0.612 |
Age, median (IQR) | 43 (36–50) | 42 (35–50) | 45 (38–51) | 44 (38–49) | 0.065 |
Mode of HIV transmission, n (%) | |||||
Heterosexual | 534 (43.0%) | 474 (44.2%) | 40 (38.5%) | 20 (31.3%) | 0.025 |
Injection drug use | 100 (8.1%) | 92 (8.6%) | 5 (4.8%) | 3 (4.7%) | |
Men who have sex with men | 533 (42.9%) | 440 (41.0%) | 54 (51.9%) | 39 (60.9%) | |
Other/unknown | 74 (6.0%) | 67 (6.2%) | 5 (4.8%) | 2 (3.1%) | |
Migrants, n (%) | 151 (12.2%) | 136 (12.7%) | 8 (7.7%) | 7 (10.9%) | 0.317 |
Previous AIDS event, n (%) | 161 (130%) | 152 (14.2%) | 8 (7.7%) | 1 (1.6%) | 0.004 |
Years of HIV infection, median (IQR) | 3.4 (1.6–6.3) | 3.3 (1.6–6.3) | 3.3 (1.6–6.5) | 4.2 (2.1–6.1) | 0.472 |
HCV Ab, n (%) | |||||
Negative | 1057 (85.2%) | 908 (84.6%) | 88 (84.6%) | 61 (95.3%) | 0.197 |
Positive | 120 (9.7%) | 109 (10.2%) | 10 (9.6%) | 1 (1.6%) | |
Unknown | 64 (5.1%) | 56 (5.2%) | 6 (5.8%) | 2 (3.1%) | |
CD4 before cART start, n (%) | |||||
< 200 | 368 (29.7%) | 334 (31.1%) | 24 (23.1%) | 10 (15.6%) | 0.047 |
201–350 | 399 (32.2%) | 344 (32.1%) | 29 (27.9%) | 26 (40.6%) | |
351–500 | 307 (24.7%) | 258 (24.0%) | 30 (28.9%) | 19 (29.7%) | |
500+ | 143 (11.5%) | 116 (10.8%) | 18 (17.3%) | 9 (14.1%) | |
Missing | 24 (1.9%) | 21 (2.0%) | 3 (2.8%) | – | |
HIV RNA before cART start, n (%) | |||||
< 20,000 | 337 (27.2%) | 279 (26.0%) | 37 (35.5%) | 21 (32.8%) | 0.385 |
20,000–100,000 | 410 (33.0%) | 358 (33.3%) | 30 (28.9%) | 22 (34.4%) | |
100,000–250,000 | 235 (18.9%) | 207 (19.3%) | 18 (17.3%) | 10 (15.6%) | |
250,000+ | 233 (18.8%) | 208 (19.4%) | 15 (14.4%) | 10 (15.6%) | |
Missing | 26 (2.1%) | 21 (2.0%) | 4 (3.9%) | 1 (1.6%) | |
CD4 at switch, median (IQR) | |||||
< 350 | 219 (17.7%) | 199 (18.6%) | 14 (13.5%) | 6 (9.4%) | 0.008 |
350–500 | 285 (23.0%) | 255 (23.8%) | 23 (22.1%) | 7 (10.9%) | |
500+ | 737 (59.3) | 619 (57.6%) | 67 (64.4%) | 51 (79.7%) | |
CD4 at switch, median (IQR) | 554 (402–740) | 547 (394–729) | 600 (426–819) | 614 (506–807) | 0.012 |
CD8 at switch, median (IQR) | 824 (600–1118) | 832 (601–1121) | 797 (587–1124) | 768 (597–1009) | 0.467 |
CD4/CD8 ratio at switch, median (IQR) | 0.69 (0.45–0.98) | 0.67 (0.44–0.97) | 0.78 (0.51–1.10) | 0.83 (0.58–1.09) | 0.008 |
CD4/CD8 ratio at switch > = 1, n (%) | 303 (24.4%) | 256 (23.9%) | 29 (27.9%) | 18 (28.1%) | 0.513 |
Months of antiretroviral exposure, median (IQR) | 18 (9–34) | 17 (8–35) | 18 (12–36) | 20 (12–31) | 0.184 |
Months of viral suppression, median (IQR) | 21 (11–39) | 21 (10–39) | 20 (12–37) | 20 (13–34) | 0.824 |
Reason for switch, n (%) | |||||
Toxicity | 330 (26.6%) | 294 (27.4%) | 27 (26.0%) | 9 (14.1%) | < 0.001 |
Simplification | 493 (39.6%) | 407 (38.0%) | 42 (40.4%) | 44 (68.7%) | |
Patient’s decision | 18 (1.5%) | 17 (1.6%) | 0 (0.0%) | 1 (1.6%) | |
Other | 387 (31.2%) | 346 (32.2%) | 31 (29.8%) | 10 (15.6%) | |
Missing | 13 (1.1%) | 9 (0.8%) | 4 (3.8%) | 0 (0.0%) |